2021-08-004 - ARVIS - ARTIFICIAL VISION SYSTEM

ARVIS

2021-08-004

A vision system based on a camera glasses, a high energy efficient light emitter-power supply system, and a retinal prosthesis comprising a photodetector, a photovoltaic cell and a chip (IVision ASIC). Selectively activate pixels generating high quality images (technology protected by IFAE), stimulating eye neurons of blind patients by using a graphene flexible and biocompatible multi-electrode array, increasing the signal conductivity (technology protected by ICN2)

Social and environmental advantages for welbeing, reducing dependence of blind people and reducing pain treatments for the public health system due to in-home applications.

Enabling vision for blind people and removing side-effects of drugs used by patients suffering pain or other disorders associated to brain diseases

Retinal prostheses have recently been developed to restore useful vision to individuals blinded by outer retinal diseases such as retinitis pigmenotsa. The quality of vision restored is limited due to the low density of electrodes hosted in the current retinal chips and also depends on the distance of the electrodes to the retina. Power supply limitation due to high energy demand when using a multielectrode system. The ARVIS technology is a highly energy efficient and low complexity system for artificial vision devices, providing high quality images thanks to the combination of several subsystems: a video camera glasses, a processing image / power supply system coupled to a retinal implant composed of a photodetection/PV system, a dedicated ASIC and an electrode array.

20570000000

1457898750

83308500

The Retinal Implants Market Size was valued at USD 20.57 billion in 2022. The Retinal Implants market industry is projected to grow from USD 23.91 billion in 2024 to USD 46.05 billion by 2032, exhibiting compound annual growth rate (CAGR) of 8.54% during the forecast period (2024 - 2032). Retinal implants and prostheses R&D has increased in recent years owing to their immense market potential and surging awareness initiatives, advancements in technologies leading to novel product launchesare the key market drivers enhancing the market growth. Source: https://www.marketresearchfuture.com/reports/retinal-implants-market-6580

The rise in the geriatric population that is vulnerable to eye diseases drives the growth of the artificial retina market during the forecast period. For instance, according to the review article "Macular Degeneration" of the National Library of Medicine, published in August 2022, age-related macular degeneration (ARMD) is the most common cause of blindness prevalent in developed countries, particularly in people older than 60 years. According to the same source, AMRD accounts for 8.7% of all types of blindness worldwide. According to the article published in Geriatric Ophthalmology, in January 2021, 3.6 million individuals, or 18% of people over 70, were visually impaired. This factor increases the market CAGR in the forecast period. Source: https://www.marketresearchfuture.com/reports/retinal-implants-market-6580

Retinal Implants Market Segment Insights Based on Type, the Retinal Implants market segmentation includes Argus II (50%), Implantable Miniature Telescope, and Retina Implant Alpha AMS. The Argus II segment dominated the market due to the increasing adoption of these devices ly as implants, technological advancements, and novel product launches. Source: https://www.marketresearchfuture.com/reports/retinal-implants-market-6580

Retinal Implant readout + communications chip design and clinical tests

5M€ (1+4)

Producte proposal; Patent licensing

Enabling vision to blind patients / Mitigation of motor and/or pain disorders motivated by brain diseases (Parkinson, epilepsia, etc) with minimally invasive imlpants wilrelessly controllable.

R&D development is expensive; product certification needs

Engaging of an EU retinal implant company in a pilot for testing and validation of the PoC. Licensing of the technology. The IFAE's patent value is higher than 50% most similar 100 patents. Patent value = Patent impact (forward citations) + Market strategy (protected countries' gdp) / patent age

2 patent families granted in the main geographic areas (EU, USA, CN, JP): 1) Artificial vision system patent; 2) Psk modulation method and demodulator thereof

Patent ready for licensing (TRL 4). Partnership: IFAE, ICFO, ICN2, Barraquer, Institut de la Vision-Sorbonne University.

Patents: PCT/EP2019/079522 - WO2020089222 - Date: Oct 29th, 2019 Status: Granted URL: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020089222